Relationship between the prevalence of anti-glutamic acid decarboxylase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 11, 2004, Pages 1645-1650

  Rodacki, Melanie ^a,b,c,d   Zajdenverg, L ^a   Albernaz, M S ^a   Bencke Goncalves M R ^a   Milech, A ^a   Oliveira, J E P ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NONE   (United States)

Author keywords

Anti GAD65 auto antibodies; Time from diagnosis; Type 1 diabetes mellitus

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY;

ADOLESCENT; ADULT; AGE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BRAZIL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE DURATION; ETHNOLOGY; FEMALE; FREQUENCY ANALYSIS; GENDER; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERVIEW; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; RADIOIMMUNOASSAY; STATISTICAL SIGNIFICANCE;

EID: 9244260600     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004001100008     Document Type: Article

References (30)

1. Winter WE, Harris N & Schatz D (2002). Immunological markers in the diagnosis and prediction of autoimmune type 1 A diabetes. Clinical Diabetes, 20: 183-191.
2. American Diabetes Association (1997). Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 20: 1183-1201.
3. Zimmet PZ (1995). The pathogenesis and prevention of diabetes in adults. Diabetes Care, 18: 1050-1064.
4. Nazaimoon WM, Azmi KN, Rasat R, Ismail IS, Singaraveloo M, Mohamad WB, Letchuman R, Sheriff IH, Faridah I & Khalid BA (2000). Autoimmune markers in young Malaysian patients with type 1 diabetes mellitus. Medical Journal of Malaysia, 55: 318-323.
5. Pardini VC, Mourao DM, Nascimento PD, Vivolo MA, Ferreira SR & Pardini H (1999). Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients. Brazilian Journal of Medical and Biological Research, 32: 1195-1198.
6. Yokota I, Matsuda J, Naito E, Ito M, Shima K & Kuroda Y (1998). Comparison of GAD and ICA512/IA-2 antibodies at and after the onset of IDDM. Diabetes Care, 21: 49-52.
7. Imagawa A, Itoh N, Hanafusa T et al. (1996). High prevalence of antibodies to glutamic acid decarboxylase in comparison to islet cell antibodies in patients with long-standing insulin-dependent diabetes mellitus. Research Communications in Molecular Pathology and Pharmacology, 92: 43-52.
8. Covic AM, Schelling JR, Constantiner M, Iyengar SK & Sedor JR (2000). Serum C-peptide concentrations poorly phenotype type 2 end-stage renal disease patients. Kidney International, 58: 1742-1750.
9. Berger B, Stenstrom G & Sundkvist G (2000). Random C peptide in the classification of diabetes. Scandinavian Journal of Clinical and Laboratory Investigation, 60: 687-693.
10. Cravarezza P, Radaeli E, Toffoli C & Rigosa C (1986). Discrimination of type I from insulin treated type II diabetic patients by C-peptide measurement. Acta Diabetologica Latina, 23: 345-350.
11. Palatnik M, Silva Junior WA, Estalote AC, Oliveira JEP, Milech A & Zago MA (2002). Ethnicity and type 2 diabetes in Rio de Janeiro, Brazil, with a review of the prevalence of the disease in Amerindians. Human Biology, 74: 533-544.
12. Elkadhi A, Khelifi N, Abid A, Nagati K, Jenhani F & Ben Rayana MC (2002). Prevalence of anti-GAD autoantibodies in Tunisian children with type 1 diabetes. Tunisie Médicale, 80: 281-285.
13. Schmidli RS, DeAizpurua HJ, Harrison LC & Colman PG (1994). Antibodies to glutamic acid decarboxylase in at-risk and clinical insulin-dependent diabetic subjects: relationship to age, sex and islet cell antibody status, and temporal profile. Journal of Autoimmunity 7: 55-66.
14. Chen BH, Chung SB, Chiang W & Chao MC (2001). GAD65 antibody prevalence and association with thyroid antibodies, HLA-DR in Chinese children with type 1 diabetes mellitus. Diabetes Research and Clinical Practice, 54: 27-32.
15. Thai AC, Ng WY, Loke KY, Lee WR, Lui KF & Cheah JS (1997). Anti-GAD antibodies in Chinese patients with youth and adult-onset IDDM and NIDDM. Diabetologia, 40: 1425-1430.
16. Aguilera E, Recasens M, Morinigo RA, Casamitjana R, Oriola J, Ercilla G & Conget I (2003). Clinical, metabolic, immunologic and genotypic characteristics in non-pediatric patients with type 1A diabetes mellitus. Onset and short-term prognosis. Medicina Clí nica, 120: 121-124.
17. Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, Salmela PI & Knip M (2000). Genetic, autoimmune, and clinical characteristics of childhood and adult onset type 1 diabetes. Diabetes Care, 23: 1326-1332.
18. Vandewalle CL, Falorni A, Svanholm S, Lernmark A, Pipeleers DG & Gorus FK (1995). High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. Journal of Clinical Endocrinology and Metabolism, 80: 846-851.
19. Hosszufalusi N, Vatay A, Rajczy K et al. (2003). Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care, 26: 452-457.
20. Prado Jr C (2000). Formação do Brasil Contemporâneo. Editora Brasiliense/Publifolha, São Paulo, SP, Brazil, 81-113.
21. Fernandes APM, Louzada-Junior P, Foss MC & Donadi EA (2002). HLA DRB1, DQB1 and DQA1 allele profile in Brazilian patients with type 1 diabetes mellitus. Annals of the New York Academy of Sciences, 958: 305-308.
22. Marques SBD, Volpini W, Caillat Zucman S, Leiber SR, Pavin EJ & Persoli LB (1998). Distribution of HLA-DRB1 alleles in a mixed population with insulin dependent diabetes mellitus from Southeast of Brazil. Brazilian Journal of Medical and Biological Research, 31: 365-368.
23. Panz VR, Kalk WJ, Zouvanis M & Joffe BI (2000). Distribution of autoantibodies to glutamic acid decarboxylase across the spectrum of diabetes mellitus seen in South Africa. Diabetic Medicine, 17: 524-527.
24. Cesarini PR, Mendonça E, Fernandes V, Silva RC, Morimitsu LK, Garcia FE, Vechiatti S, Miranda WL & Dib SA (2003). Prevalê ncia dos marcadores imunológicos anti-GAD e anti-IA2 em parentes de primeiro grau de diabéticos do tipo 1 em amostra da populaç ão da Grande São Paulo. Revista da Associação Médica Brasileira 49: 395-400.
25. Chuang LM, Lin CY, Wu HP, Tsai WY, Tai TY & Lin BJ (1997). Anti-GAD65 autoantibody in Taiwanese patients with insulin-dependent diabetes mellitus: effect of HLA on anti-GAD65 positivity and clinical characteristics. Clinical Endocrinology, 47: 455-461.
26. Medici F, Hawa MI, Giorgini A, Panelo A, Solfelix CM, Leslie RD & Pozzilli P (1999). Antibodies to GAD65 and a tyrosine phosphatase-like molecule IA-2ic in Filipino type 1 diabetic patients. Diabetes Care, 22: 1458-1461.
27. Borg H, Gottsater A, Fernlund P & Sundkvist G (2002). A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes, 51: 1754-1762.
28. Jaeger C, Allendorfer J, Hatziagelaki E, Dyrberg T, Bergis KH, Federling K & Bretzel RG (1997). Persistent GAD65 antibodies in longstanding IDDM are not associated with residual beta cell function, neuropathy and HLA DR status. Hormone and Metabolic Research, 29: 510-515.
29. Zanone MM, Catalfamo E, Pietropaolo SL, Rabbone I, Sacchetti C, Cerutti F, Trucco M & Cavallo-Perin P (2003). Glutamic acid decarboxylase and ICA512/IA-2 autoantibodies as disease markers and relationship to residual beta-cell function and glycemic control in young type 1 diabetic patients. Metabolism, 52: 25-29.
30. Hermitte L, Atlan-Gepner C, Dufayet D, Jannot MF, Christofilis MA, Nervi S & Vialettes B (1998). Diverging evolution of anti-GAD and anti-IA2 antibodies in long-standing diabetes mellitus as a function of age at onset: no association with complications. Diabetic Medicine, 15: 586-591.